The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Sunil Sharma, Tithi Ghosh et al.|PLoS ONE|2020Cited by 82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cellsSumati Gupta, S. Sharma, Alexis Weston et al.|Prostate Cancer and Prostatic Diseases|2016Cited by 47
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cellsSumati Gupta, Sunil Sharma, Kelly Doyle et al.|Oncotarget|2018Cited by 27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial CarcinomaSumati Gupta, Sunil Sharma, Daniel J. Albertson et al.|Molecular Cancer Therapeutics|2018Cited by 24
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Sunil Sharma, Tithi Ghosh et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 19